Objective:
To discuss the entry of Humira biosimilars into the US market and the challenges they may face.
Approach:
- Market Entry: The first Humira biosimilar, Amgen’s Amjevita, is now available in the US, with more expected in 2023.
- Market Challenges: Humira's rebates may hinder biosimilars' access to formularies, and AbbVie is likely to increase rebates to maintain preferred status.
- Pricing Strategy: Amgen launched Amjevita with two list prices: one 5% lower than Humira and another with a 55% discount for some patients.
- Market Share Projections: Initial cost savings from biosimilars are expected to be minimal, with a projected market share of around 25% by 2026.
- Factors Influencing Preference: Factors such as concentration, pen-injector availability, manufacturer reputation, net costs, and supply chain security will influence payer preferences.
- Price Trends: Despite the entry of biosimilars, Vizient expects drug prices to rise by 3.78% due to inflation.
Key Findings:
- Humira biosimilars face significant market entry challenges due to existing rebates.
- AbbVie is expected to increase rebates to retain market position.
- Initial cost savings from biosimilars are projected to be minimal.
Interpretation:
Limitations:
- The analysis does not provide specific data on the long-term impact of biosimilars on pricing.
- Market dynamics may change rapidly, affecting projections.
Conclusion:
The landscape for Humira biosimilars is complex, with significant competition and pricing strategies at play.
Sources:
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
